Repligen's Wild Ride: Downgrade, Drops, and AI Hopes

Repligen stock dipped after Jefferies cut its price target, but is this a buying opportunity? Despite a nearly 20% drop this year and high volatility, the biopharma manufacturing company could still benefit from advances in generative AI, sparking investor interest. Hosted on Acast. See acast.com/privacy for more information.